Axsome Therapeutics Joins the Global Narcolepsy Community in Raising Awareness on World Narcolepsy Day
September 21 2023 - 6:00AM
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical
company developing and delivering novel therapies for the
management of central nervous system (CNS) disorders, today
announced it is joining the global narcolepsy advocacy community,
including more than 20 global patient advocacy organizations across
six continents, to raise awareness of the impact that narcolepsy
has on World Narcolepsy Day, Sept. 22, 2023.
In support of World Narcolepsy Day, Axsome is
sponsoring several awareness events:
- On Sept. 21 at 6 p.m. Eastern Time,
Axsome is sponsoring a virtual panel where an international group
of experts will discuss narcolepsy around the world, organized by
Wake Up Narcolepsy. Registration and details for the panel event
can be found here.
- On Sept. 29-Oct. 1, Axsome is a
sponsor of and is attending “Thrive Together,” Narcolepsy Network’s
37th Annual Conference, a multi-day event to learn, engage, and
connect with people with narcolepsy and their supporters, being
held in Denver, Colo. More details about the conference can be
found here.
Axsome is committed to developing innovative
therapies that make an impact on the lives of people suffering from
CNS disorders, including those with narcolepsy and other sleep
disorders. As part of that mission, Axsome’s works closely with
advocacy and other patient groups to support their efforts to
provide a network and resources for patients and their families and
to raise awareness of these conditions globally.
Narcolepsy is a serious and debilitating
neurological condition that affects one out of 2000 people
including an estimated 185,000 people in the U.S. alone. It has
been shown to occur in people of any race and most commonly shows
up in people aged 15-30. Narcolepsy has been shown to interfere
with thinking and emotional and social functioning and is
associated with increased risk of work- or driving-related
accidents including a 1.5x higher mortality rate. These statistics
highlight the significant public health burden that narcolepsy
represents, as well as a need for improvements in access to
treatments.
For more information about narcolepsy, World
Narcolepsy Day, as well as additional resources for patients,
please learn more about the following organizations and their
affiliates:
- Wake Up Narcolepsy
(https://www.wakeupnarcolepsy.org/): a nonprofit organization
dedicated to driving narcolepsy awareness, education and research
towards improved treatments and a cure.
- Narcolepsy Network
(https://narcolepsynetwork.org/): is a national patient support
organization dedicated to education, support and assistance,
advocacy, and resources for people with narcolepsy.
- Sleep Research
Society (https://sleepresearchsociety.org/): an
organization for scientific investigators who educate and research
sleep and circadian science.
- Sleep Consortium
(https://sleepconsortium.org/): a non-profit organization created
to accelerate next generation research, disease understanding, and
therapy development for those living with Central Disorders of
Hypersomnolence (CDoH) and related diseases.
- National Sleep
Foundation (https://www.thensf.org/): an independent
nonprofit, dedicated to improving overall health and well-being by
advancing sleep health.
About Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc. is a biopharmaceutical
company developing and delivering novel therapies for central
nervous system (CNS) conditions that have limited treatment
options. Through development of therapeutic options with novel
mechanisms of action, we are transforming the approach to treating
CNS conditions. At Axsome, we are committed to developing products
that meaningfully improve the lives of patients and provide new
therapeutic options for physicians. For more information, please
visit the Company’s website at axsome.com. The Company may
occasionally disseminate material, nonpublic information on the
company website.
Forward Looking Statements
Certain matters discussed in this press release
are “forward-looking statements”. We may, in some cases, use terms
such as “predicts,” “believes,” “potential,” “continue,”
“estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,”
“could,” “might,” “will,” “should” or other words that convey
uncertainty of future events or outcomes to identify these
forward-looking statements. In particular, the Company’s statements
regarding trends and potential future results are examples of such
forward-looking statements. The forward-looking statements include
risks and uncertainties, including, but not limited to, the
continued commercial success of our Sunosi® and Auvelity® products
and the success of our efforts to obtain any additional
indication(s) with respect to solriamfetol and/or AXS-05; the
success, timing and cost of our ongoing clinical trials and
anticipated clinical trials for our current product candidates,
including statements regarding the timing of initiation, pace of
enrollment and completion of the trials (including our ability to
fully fund our disclosed clinical trials, which assumes no material
changes to our currently projected revenues or expenses), futility
analyses and receipt of interim results, which are not necessarily
indicative of the final results of our ongoing clinical trials,
and/or data readouts, and the number or type of studies or nature
of results necessary to support the filing of a new drug
application (“NDA”) for any of our current product candidates; our
ability to fund additional clinical trials to continue the
advancement of our product candidates; the timing of and our
ability to obtain and maintain U.S. Food and Drug Administration
(“FDA”) or other regulatory authority approval of, or other action
with respect to, our product candidates, including statements
regarding the timing of any NDA submission; whether issues
identified by FDA in the complete response letter may impact the
potential approvability of the Company’s NDA for AXS-07 for the
acute treatment of migraine in adults with or without aura,
pursuant to our special protocol assessment for the MOMENTUM
clinical trial; the Company’s ability to successfully defend its
intellectual property or obtain the necessary licenses at a cost
acceptable to the Company, if at all; the successful implementation
of the Company’s research and development programs and
collaborations; the success of the Company’s license agreements;
the acceptance by the market of the Company’s products and product
candidates, if approved; the Company’s anticipated capital
requirements, including the amount of capital required for the
continued commercialization of Sunosi and Auvelity and for the
Company’s commercial launch of its other product candidates, if
approved, and the potential impact on the Company’s anticipated
cash runway; unforeseen circumstances or other disruptions to
normal business operations arising from or related to COVID-19; and
other factors, including general economic conditions and regulatory
developments, not within the Company’s control. The factors
discussed herein could cause actual results and developments to be
materially different from those expressed in or implied by such
statements. The forward-looking statements are made only as of the
date of this press release and the Company undertakes no obligation
to publicly update such forward-looking statements to reflect
subsequent events or circumstance.
Axsome Contacts:
Investors:Mark JacobsonChief Operating OfficerAxsome
Therapeutics, Inc.One World Trade Center, 22nd FloorNew York, NY
10007Tel: 212-332-3243Email: mjacobson@axsome.com
www.axsome.com
Media:
Darren OplandDirector, Corporate CommunicationsAxsome
Therapeutics, Inc.One World Trade Center, 22nd FloorNew York, NY
10007Tel: 929-837-1065Email: dopland@axsome.com www.axsome.com
Axsome Therapeutics (NASDAQ:AXSM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Axsome Therapeutics (NASDAQ:AXSM)
Historical Stock Chart
From Sep 2023 to Sep 2024